Funds like the Vanguard S&P 500 ETF have a dividend yield of 1.1%, so to find no-brainer dividend stocks to buy now, we'll want choices that far outstrip that yield, provide stability, and have a ...
AbbVie’s immunology heirs Skyrizi and Rinvoq are proving booming growth to make up for once-king Humira’s continuous sales slide. With an upcoming FDA decision for Skyrizi and a new edge over a major ...
One key reason AbbVie has outperformed the market this year is that it has performed well financially. Through the first nine ...
People with Crohn’s disease often take medicines to help manage their condition and improve their symptoms. Some of these medicines are taken by mouth and stay inside of the digestive tract. But ...
Skyrizi was the top Rx and over-the-counter (OTC) pharma brand during July, according to data released by iSpot.tv on Monday afternoon. Skyrizi recorded an impressions share of voice (SOV) of 5.18%, ...
AbbVie has received European Commission approval of its anti-inflammation drug Skyrizi for the treatment of adult patients with moderately to severely active ulcerative colitis, the pharmaceutical ...
AbbVie’s ABBV key top-line drivers are its newer immunology medicines, Rinvoq and Skyrizi. Sales of both these drugs have effectively replaced the company’s flagship drug, Humira, which began facing ...
Skyrizi has knocked Dupixent off its pedestal and claimed the top spot for ad impressions by Rx and over-the-counter (OTC) brands in April. The treatment for Crohn’s disease, psoriasis and psoriatic ...
After Rinvoq won two new indications in as many months, AbbVie's immunology compatriot Skyrizi is getting in on the approval action. Skyrizi clinched a second nod, this time to treat adults with ...
Although many people with plaque psoriasis can control their symptoms by using topical treatments that are applied to the skin, some people with moderate or severe plaque psoriasis do not get enough ...
- SKYRIZI is now the only four-dose-a-year biologic for psoriasis with options to administer via a single-dose pen or prefilled syringe "We know many people living with psoriasis are looking for ...
Zacks Investment Research on MSN
ABBV vs. AZN: Which pharma stock is the better investment now?
AbbVie ABBV and AstraZeneca AZN are both global healthcare companies with diversified drug portfolios. Both companies have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback